CORT Share Price

Open 11.34 Change Price %
High 12.12 1 Day 0.84 7.48
Low 11.22 1 Week 1.38 12.91
Close 12.07 1 Month 0.18 1.51
Volume 964898 1 Year 6.77 127.74
52 Week High 12.51
52 Week Low 4.95
CORT Important Levels
Resistance 2 12.90
Resistance 1 12.56
Pivot 11.80
Support 1 11.58
Support 2 11.24
NASDAQ USA Most Active Stocks
DCTH 0.27 22.73%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
RLOG 0.45 32.35%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HAUP 0.10 25.00%
AMCN 2.36 23.56%
DCTH 0.27 22.73%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
PTSX 0.12 -40.00%
More..

Corcept Therapeutics Incorporated (NASDAQ: CORT)

CORT Technical Analysis 5
As on 21st Jun 2017 CORT Share Price closed @ 12.07 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 8.33 & Strong Buy for SHORT-TERM with Stoploss of 10.72 we also expect STOCK to react on Following IMPORTANT LEVELS.
CORT Target for June
1st Target up-side 13.22
2nd Target up-side 14.55
3rd Target up-side 15.89
1st Target down-side 9.4
2nd Target down-side 8.07
3rd Target down-side 6.73
CORT Other Details
Segment EQ
Market Capital 189395360.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.corcept.com
CORT Address
CORT
149 Commonwealth Drive
Menlo Park, CA 94025
United States
Phone: 650-327-3270
Fax: 650-327-3218
CORT Latest News
Interactive Technical Analysis Chart Corcept Therapeutics Incorporated ( CORT NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Corcept Therapeutics Incorporated
CORT Business Profile
Corcept Therapeutics Inc is a United States-based pharmaceutical company. The Company is involved in the discovery and development of drugs that regulate the effects of cortisol or also known as the stress hormone. Founded on 1998, it has focused its research and clinical development activity on drugs that block the glucocorticoid receptor or GR-II receptor, one of the bodys two receptors of cotrisol. Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.